Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Apremilast Nanoparticles in Plaque Psoriasis
NCT07366268Not yet recruiting
- Sponsor
- Assiut University
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of apremilast in plaque psoriasis (3 arms), sponsored by Assiut University. Primary endpoint: Thickness, Erythema, and Scaling Score at 20 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07366268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366268.